Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-CARBO: Carboplatin in Metastatic Castration-Resistant Prostate Cancer With HR Pathway Alterations
NCT03652493Phase 2Completed
- Sponsor
- Centre François Baclesse
- Start
- Sep 2018
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in castration-resistant prostate cancer (CRPC), sponsored by Centre François Baclesse. Primary endpoints: Best Radiological Tumoral Response Rate at 27 weeks and Biological Response Rate Defined by Value of PSA at 27 weeks. Started Sep 2018; status: completed.
02
Drugs
carboplatin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03652493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652493.